-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MO8P0dvRZsS5KoWaCAYn7ArA3YUj0v3d+7kCNTAyUot06twYb0K+yGeO8qHJS6g4 ixjkCHvzVfvLXc0D5jIi7w== 0001079974-08-000285.txt : 20080229 0001079974-08-000285.hdr.sgml : 20080229 20080229170509 ACCESSION NUMBER: 0001079974-08-000285 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080225 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20080229 DATE AS OF CHANGE: 20080229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-26787-D FILM NUMBER: 08656790 BUSINESS ADDRESS: STREET 1: 8022 SOUTHPARK CIRCLE STREET 2: SUITE 100, CITY: LITTLETON STATE: CO ZIP: 80120 BUSINESS PHONE: (303) 703-4906 MAIL ADDRESS: STREET 1: 8022 SOUTHPARK CIRCLE STREET 2: SUITE 100, CITY: LITTLETON STATE: CO ZIP: 80120 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 FORMER COMPANY: FORMER CONFORMED NAME: ARIZONA VENTURES INC DATE OF NAME CHANGE: 20030115 8-K 1 zynex8k_2292008.htm REPORT 8-K xynex8k_2292008.htm


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):   February 26, 2008

 
 Zynex Medical Holdings, Inc. 
(Exact name of Registrant as specified in its charter)

Nevada
33-26787-D
90-0275169
(State or other
(Commission
(I.R.S. Employer
Jurisdiction
File Number)
Identification No.)
of incorporation)
    


8022 Southpark Cir, Suite 100, Littleton, CO
80120
(Address of principal executive offices)
(Zip Code)
   

Registrant’s telephone number:  (303) 703-4906

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

[  ]           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
 
 
 
 

 
 
Item 1.02.  Termination of a Material Definitive Agreement and
 
Item 3.02   Unregistered Sales of Equity Securities

On January 25, 2008, Zynex Medical Holdings, Inc. (“Zynex”) notified holders of warrants issued by Zynex in 2006 and 2007 pursuant to a private placement that such warrants would terminate 30 days following the notice.  The termination of the warrants was permitted because Zynex’s stock has traded in excess of 200% of the exercise price of the warrants for more than 10 consecutive days.  As a result, each warrant holder had 30 days from the date of such notice to exercise their warrants or the warrants would terminate.

By February 26, 2008, all of the warrants were exercised.  Zynex issued 1,740,000 shares of common stock for an exercise price of $0.39 per share, or an aggregate exercise price of $678,600.  Each of the recipients of the common stock represented to Zynex that it is an accredited investor, and Zynex believes that the sale of its common stock pursuant to the warrant exercise is exempt from registration under Rule 506 promulgated under the Securities Act of 1933, as amended.  Zynex will use the exercise price proceeds for working capital purposes.

The common stock received pursuant to the exercise of warrants is included on a currently effective registration statement on Form SB-2 (SEC file number 333-148906) and may be resold under such registration statement.


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on as its behalf by the undersigned hereunto duly authorized.

 

                                Zynex Medical Holdings, Inc.
                                     (Registrant)



Date:  February 29, 2007                                  By:  /s/ Thomas Sandgaard
Thomas Sandgaard
President and Chief Executive Officer
 
 
 
 

 
 -----END PRIVACY-ENHANCED MESSAGE-----